Leuprorelin - CAS 53714-56-0
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
GNRH Receptor
Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer.
Publictions citing BOC Sciences Products
  • >> More
Lyophilised solid
Leuprolide; Eligard; H-Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt;
Soluble in DMSO
Store at -20 °C
An agonist at pituitary GnRH receptors
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
1.44 g/cm3
Canonical SMILES:
Current Developer:
1.Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phas
Kurebayashi J1, Toyama T2, Sumino S3, Miyajima E3, Fujimoto T3. Breast Cancer. 2016 Mar 26. [Epub ahead of print]
BACKGROUND: Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month depot formulation, TAP-144-SR (3M) 11.25 mg in postoperative, premenopausal patients with hormone receptor-positive breast cancer.
2.A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK1, Goldfarb DS2, Howland MA3,4, Kavcsak K5, Lugassy DM3, Smith SW3. J Med Toxicol. 2016 Mar 17. [Epub ahead of print]
The human monoclonal antibody denosumab inhibits osteoclast-mediated bone resorption by binding to receptor activator of nuclear factor κB ligand (RANKL), which is upregulated by tumor cells. Denosumab is indicated to prevent skeletal-related events (SREs) from osteoporosis and metastatic bone disease. We report a case of denosumab-induced hypocalcemia to highlight potential toxicity and treatment considerations. A 66-year-old man with prostate cancer, small cell lung cancer, and bone metastases presented with fatigue, weakness, and muscle spasm. Sixteen days prior, he received cycle 6 of cisplatin and etoposide, leuprolide, and denosumab (120 mg subcutaneously). His examination demonstrated a slight resting tremor, normal strength, and negative Chvostek sign. Laboratory analysis revealed hemoglobin, 8.0 g/dL; total calcium, 5.2 mg/dL (pre-denosumab, 8.9 mg/dL); and magnesium, 0.7 mg/dL. He initially received two units packed red blood cells, intravenous calcium and magnesium, and vitamin D.
3.Simultaneous Measurement of Serum Chemical Castration Agents and Testosterone Levels Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Ko DH1, Lee K2, Jeon SH3, Song SH4, Yun YM5, Chun S1, Kim HS6, Kim JY6, In MK6, Song J7. J Anal Toxicol. 2016 Mar 17. pii: bkw017. [Epub ahead of print]
Chemical castration involves administration of drugs to prevent pathological sexual behavior, reduce abnormal sexual drive and treat hormone-dependent cancers. Various drugs have been used for chemical castration; however, substantial interindividual variability and side effects are often observed. In this study, we proposed a useful monitoring method for the application of chemical castration agents using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS). Testosterone, cyproterone acetate, medroxyprogesterone, goserelin acetate, leuprolide acetate and triptorelin acetate were analyzed by UPLC-MS-MS. The target drugs were extracted from serum samples by double protein precipitation using methanol. Testosterone-1,2-d2 and buserelin acetate were used as internal standards. Parameters of analytical performance were evaluated, including imprecision, linearity, ion suppression and detection capabilities. Testosterone measurements were compared with the results of immunoassays.
4.Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer.
Tan HE1, Lake F1. Respirol Case Rep. 2016 Mar 31;4(2):e00146. doi: 10.1002/rcr2.146. eCollection 2016.
Androgen blockade is standard treatment for advanced prostate cancer. We report an uncommon case of interstitial pneumonitis induced by leuprorelin acetate.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GNRH Receptor Products

CAS 76712-82-8 Histrelin

(CAS: 76712-82-8)

Histrelin is a nonapeptide analog of GnRH (gonadotropin-releasing hormone) with added potency. When present in the bloodstream, it can act on gonadotropes. Hist...

CAS 86220-42-0 Nafarelin Acetate

Nafarelin Acetate
(CAS: 86220-42-0)

Nafarelin is a GnRH (gonadotropin-releasing hormone) agonist . Its proposed mechanism of action is the desensitization of pituitary gonadotropin-releasing hormo...

CAS 148029-26-9 Alarelin

(CAS: 148029-26-9)

Alarelin, more commonly existed as Alarelin acetate, has been found to be a GnRH agonist that could delay the sexual maturation in rats.

CAS 214766-78-6 Degarelix acetate

Degarelix acetate
(CAS: 214766-78-6)

CAS 145781-92-6 Goserelin Acetate

Goserelin Acetate
(CAS: 145781-92-6)

Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pitui...

CAS 57773-65-6 Deslorelin

(CAS: 57773-65-6)

Deslorelin is a synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone super-agonist (GnRH agonist) with potential antineoplastic activit...

Triptorelin pamoate
(CAS: 124508-66-3)

Triptorelin is a decapeptide as a GnRH (gonadotropin-releasing hormone) agonist under the development of Pfizer. It decreases pituitary secretion of gonadotropi...

CAS 34973-08-5 Gonadorelin acetate

Gonadorelin acetate
(CAS: 34973-08-5)

Gonadorelin a synthetic decapeptide prepared for gonadotropin-releasing hormone (GnRH), affects follicle stimulating hormones.

CAS 834153-87-6 Elagolix

(CAS: 834153-87-6)

Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ult...

CAS 65807-02-5 Goserelin Acetate

Goserelin Acetate
(CAS: 65807-02-5)

CAS 79561-22-1 Alarelin Acetate

Alarelin Acetate
(CAS: 79561-22-1)

Alarelin acetate is a synthetic Gonadotrophin-releasing hormone agonist. It is the acetate form of a hypothalamic peptide. It is a potent LH-RH agonist in rats ...

CAS 53714-56-0 Leuprorelin

(CAS: 53714-56-0)

Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer.

CAS 832720-36-2 Elagolix sodium

Elagolix sodium
(CAS: 832720-36-2)

Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of end...

CAS 33515-09-2 Gonadorelin

(CAS: 33515-09-2)

Gonadorelin, a synthetic decapeptide prepared using solid phase peptide synthesis, is another name for gonadotropin-releasing hormone (GnRH) for evaluating th...

CAS 74381-53-6 Leuprolide Acetate

Leuprolide Acetate
(CAS: 74381-53-6)

Chemical Structure

CAS 53714-56-0 Leuprorelin

Quick Inquiry

Verification code

Featured Items